Aquestive Therapeutics Inc., a pharmaceutical company focused on advancing medicines through innovative science and delivery technologies, announced upcoming presentations of positive data from pharmacokinetic and pharmacodynamic studies on Anaphylm™ (epinephrine) Sublingual Film. These findings, concerning the treatment of severe allergic reactions including anaphylaxis, will be showcased at the Center for Food Allergy and Asthma Research (CFAAR) Food Allergy Summit in Chicago from June 27-29, 2025. The data, previously presented at the 2025 AAAAI Annual Meeting, highlights Anaphylm as potentially the first orally delivered epinephrine option in the United States, pending FDA approval. Poster presentations will cover the physicochemical properties of Anaphylm under extreme conditions and its rapid pharmacokinetic and pharmacodynamic responses, scheduled for June 28 from 5:00 PM to 7:30 PM CST. Abstracts are accessible on the company's website in the Scientific Events section.